Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort

Pharmacogenomics

Volumn 17, Issue 7, 2016, Pages 715-720

  Smith, Samantha Louise ^a   Plant, Darren ^a   Lee, Xiu Hue ^a   Massey, Jonathan ^a   Hyrich, Kimme ^a   Morgan, Ann W ^b   Wilson, Anthony G ^c   Isaacs, John ^d   Barton, Anne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

biomarker; rheumatoid arthritis; single nucleotide polymorphism; TNF inhibitors; treatment response

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; ORGANIC ANION TRANSPORTER; PDE3A PROTEIN, HUMAN; PHOSPHODIESTERASE III; SLCO1C1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PDE3A GENE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1C1 GENE; UNITED KINGDOM; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED KINGDOM;

EID: 84973515323     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.16.16     Document Type: Article

References (16)

1. Liu C, Batliwalla F, Li W et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9-10), 575-81 (2008).
2. Plant D, Bowes J, Potter C et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 63(3), 645-53 (2011).
3. Krintel SB, Palermo G, Johansen JS et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22(8), 577-589 (2012).
4. Umicevic MM, Cui J, Vermeulen SH et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann. Rheum. Dis. 72(8), 1375-1381 (2013).
5. Cui J, Stahl EA, Saevarsdottir S et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 9(3), e1003394 (2013).
6. Julià A, Fernandez-Nebro A, Blanco F et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 16(2), 147-150 (2016).
7. Acosta-Colman I, Palau N, Tornero J et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14(7), 727-734 (2013).
8. Potter C, Hyrich KL, Tracey A et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 69-74 (2009).
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44-48 (1995).
10. Purcell S, Neale B, Todd-Brown K et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
11. PLINK (version 1.07) 2007. http://pngu.mgh.harvard.edu/purcell/plink/
12. Quanto (version 1.2.4) 2009. http://hydra.usc.edu/gxe
13. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12), 1558-1565 (2006).
14. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63(5), 508-516 (2004).
15. Wells G, Becker JC, Teng J et al. Validation of the 28-joint Disease activity score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68(6), 954-960 (2009).
16. Jurado RL. Why shouldn't we determine the erythrocyte sedimentation rate Clin. Infect. Dis. 33(4), 548-549 (2001).